Early Structural Valve Deterioration After TAVR and Potential Association With Long-Term Corticosteroid Therapy: A Case Report

Clicks: 7
ID: 332042
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #384 of 408 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Early structural valve deterioration (SVD) after transcatheter aortic valve replacement (TAVR) for aortic stenosis is uncommon, particularly within 5 years post-implantation. The impact of long-term corticosteroid therapy on transcatheter bioprosthetic valve durability remains poorly understood. Case Presentation An 80-year-old woman presented with severe calcific SVD 4.5 years after undergoing TAVR with a balloon-expandable transcatheter aortic valve, requiring surgical explantation and aortic valve replacement. She had received long-term corticosteroid therapy for bullous pemphigoid for over 9 years, complicated by steroid-induced diabetes mellitus and progressive chronic kidney disease. While post-procedural echocardiography initially confirmed favorable valve function (peak velocity 2.5 m/s, mean gradient 14.2 mmHg), follow-up echocardiography revealed Stage3 (severe) hemodynamic SVD, with a markedly reduced effective orifice area of 0.48 cm2 and an elevated peak/mean gradient of 139.2/80.1 mmHg (peak velocity 5.9 m/s). Computed tomography revealed marked leaflet calcification without evidence of hypoattenuated leaflet thickening or thrombosis. Pathological examination of the explanted valve confirmed advanced intrinsic and extrinsic calcific degeneration without active inflammation. Although moderate patient–prosthesis mismatch was present, these findings suggest that the patient’s systemic pro-calcific metabolic environment—driven by prolonged corticosteroid therapy and its associated metabolic comorbidities—might have played a key role in accelerating SVD. Discussion While hypothesis-generating, our findings suggest that long-term corticosteroid therapy and associated metabolic disorders might contribute to early transcatheter valve deterioration. Careful echocardiographic follow-up should be considered in post-TAVR patients with complex metabolic risk profiles.
Reference Key
openalex_W7221332473 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shiori Fuse, Teruo Sekimoto, Taka-aki Matsuyama, Hiroki Yamaguchi, Toshiro Shinke
Are you one of these authors? Claim your profile
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag747
URL
https://doi.org/10.1093/ehjcr/ytag747
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.